Heron Therapeutics (HRTX) Depreciation & Amortization (CF) (2010 - 2026)

Heron Therapeutics has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $529000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 3.99% year-over-year to $529000.0; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 2.63% YoY), and the FY2025 full-year result was $2.3 million, down 7.14% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $529000.0, down from $537000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $791000.0 in Q4 2022, with the low at $529000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $654352.9 across 5 years, with a median of $671000.0 in 2022.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) advanced 10.13% — and 2024, when it declined 20.08%.
• Heron Therapeutics' Depreciation & Amortization (CF) stood at $791000.0 in 2022, then declined by 9.48% to $716000.0 in 2023, then fell by 18.85% to $581000.0 in 2024, then fell by 7.57% to $537000.0 in 2025, then fell by 1.49% to $529000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $529000.0 (Q1 2026), $537000.0 (Q4 2025), and $615000.0 (Q3 2025), per Business Quant data.